In-Vitro Acetylcholine Esterase Enzyme Inhibition Potential of Siddha Formulation Vilvaver Chooranam: A Neuroprotective Assay

Abstract

Background and Aim: Alzheimer's disease (AD) is a progressive neurodegenerative condition evidenced by significant cognitive dysfunction. The state of cognitive impairment is made worse by increased levels of the enzyme acetylcholinesterase (AChE), which is crucial in the hydrolysis of the neurotransmitter acetylcholine (ACh). Siddha therapy gaining higher momentum in recent days due to its global acceptance considering its broad spectral safety and therapeutic window. Siddha originated from the southern geographic landscape of Asia now spreading its wings across the bounders in managing dreadful diseases like AD. The main objective of the present study is to evaluate AChE inhibition of the Siddha formulation Vilvaver Chooranam (VVC). Materials & Methods: In-Vitro Acetylcholine esterase enzyme inhibition Potential of Siddha formulation Vilvaver Chooranam by Ellman’s method. Results:Results obtained from the study clearly demonstrate that the formulation VVC has shown promising acetylcholinesterase at stipulated concentration dose-dependently. Maximum percentage inhibition of about 54.53 ± 3.475 % was observed at 500μg/ml with the IC₅₀ value of 411.9 ± 30.6 µg/ml when compared to that of the Physostigmine, a known AChE Inhibitor with a maximum inhibition 93.44 ± 4.434 % at the concentration of 40μg/ml with the IC₅₀ value of 10.38± 5.29 µg/ml. Conclusion: These findings demonstrate the remarkable potential of these extracts as valuable sources of antioxidants with interesting acetylcholinesterase inhibitory activity.